Human
platelet lysate (HPL) is serum derived from platelets which acts as an
effective substitute for Fetal Bovine Serum (FBS) in cell culture applications.
It supports growth of various cell types in culture, including mesenchymal stem
cells, endothelial cells, and keratinocytes. The use of HPL avoids issues
related to animal welfare, batch-to-batch variability, and regulatory hurdles
associated with FBS.
The
global Human Platelet Lysate Market is estimated to be valued at US$ 53.0 Mn in 2023 and is expected to
exhibit a CAGR of 4.5% over the
forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increased consumption as a substitute for FBS is one of the key trends driving
the growth of the human platelet lysate market. HPL provides stable growth
environment for culturing stem cells and other cells, has low batch-to-batch
variability and is cost effective over the long run compared to FBS. It avoids
problems related to transmissible spongiform encephalopathy risks and animal
suffering associated with FBS. The substitutes market is growing as researchers
prefer using animal-free solutions in experiments. Advancements in platelet
separation technologies have further improved the efficiency and availability
of human platelet lysate products, making them a preferable substitute to FBS
in cell-based therapeutics and research.
Segment Analysis
The
Global
Human Platelet Lysate Market Demand is dominated by the autologous
segment. The autologous segment currently holds around 80% of the overall
market share owing to the reduced risk of transfusion-transmitted infections
and immune reactions associated with autologous platelet lysate products.
Several growth factors and cytokines present in autologous platelet lysate
promote cell growth and proliferation making it a suitable culture medium for
cell-based therapies.
Key Takeaways
Regional analysis: Europe dominates the global human platelet lysate market
with over 40% market share. Presence of favorable government regulations and
investments to support tissue engineering and regenerative medicine research in
countries like Germany, UK, and France have promoted the adoption of human
platelet lysate products in the region.
Key players: Key players operating in the human platelet lysate market are
STEMCELL Technologies Inc., Merck KGaA, Mill Creek Life Sciences, Merck &
Co., Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA,
Trinova Biochem GmbH, PL BioScience GmbH, Cook Regentec, Life Science Group
Ltd., BBI Solutions, Regenexx, Thermo Fisher Scientific. STEMCELL Technologies
Inc. and Merck KGaA currently account for over 35% of the global market share
due to their diverse product portfolio and strong distribution network across
major markets.
The global human platelet lysate market is expected to witness high growth over
the forecast period of 2023-2030. Rapid expansion of cell-based therapies and
regenerative medicine sector has accelerated the demand for human platelet
lysate as an alternative to fetal bovine serum. Stringent regulatory norms
favoring xeno-free cell culture practices is further promoting adoption of
human platelet lysate products.
Get
more insights on this topic:
https://www.marketwebjournal.com/human-platelet-lysate-market-market-size-and-share-analysis/
Comments
Post a Comment